Other grades of this product :
| CETRORELIX Basic information |
| Product Name: | CETRORELIX | | Synonyms: | D 20761;D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-, acetate (salt);Ns 75a;Sb 075 acetate;Cetrorelix Acetate,SB-075 acetate,NS-75A, >98%;Cetrorelix impurity;SB-075 ACETATE;NS-75A;Cetrotid | | CAS: | 145672-81-7 | | MF: | C70H92ClN17O14.C2H4O2 | | MW: | 1491.11 | | EINECS: | | Product Categories: | Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals | | Mol File: | 145672-81-7.mol |
| CETRORELIX Chemical Properties |
| storage temp. | -20°C | | solubility | methanol: soluble10% | | form | solid |
| Risk Statements | 60-63 | | Safety Statements | 22 | | WGK Germany | 3 |
| CETRORELIX Usage And Synthesis |
| Description | Cetrorelix is a synthetic peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) with a Kd value of 0.2 nM for radioligand binding to murine LTK- cells expressing human GnRHR. It inhibits the activation of hGnRHR and a downstream luciferase reporter gene in murine LTK- cells by the GnRHR agonist [D-Trp6]GnRH (IC50 = 1.2 nM). In vivo, cetrorelix (60 μg per day) reduces tumor volume to 35% of control and decreases serum luteinizing hormone levels by 50% in a human epithelial ovarian cancer mouse xenograft model. Centrorelix (0.5 mg/kg) protects the primordial follicles (PMF) in mouse ovaries from damage induced by cyclophosphamide with 65% to 86% PMF survival compared to 46% PMF survival with a saline control. Formulations containing cetrorelix have been used to prevent ovulation during in vitro fertilization. | | Uses | Cetrorelix Acetate is an gonadotropin-releasing hormone antagonist and is used to treat hormone-sensitive cancers of the prostate and breast. | | Uses | Cetrorelix, a luteinizing hormone releasing hormone receptor (LHRHR) antagonist, was used to study its safety, mechanism of action, metabolism, and efficacy as a therapeutic agent for the treatment of blood cancers such as multiple myeloma (MM). Cetrorelix is used to evaluate its effects on a wide range of physiological processes and malignancies that involve luteinizing hormone releasing hormone receptor signaling pathways involving processes such as steroidogenesis. | | Definition | ChEBI: The acetic acid salt of cetrorelix. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast. | | Biochem/physiol Actions | Cetrorelix acetate is a luteinizing hormone releasing hormone receptor antagonist. It causes prepubertal reduction in bone modeling, bone density and bone strength comparable to post-menopausal bone loss. |
| CETRORELIX Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye